Cancer/testis antigen 1 (60-72)

Cancer/testis antigen 1 (60-72) is a synthetic peptide fragment derived from the larger cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. As a defined epitope corresponding to residues 60 through 72 of the parent protein, it serves as a valuable molecular tool for dissecting immune recognition mechanisms and tumor antigenicity. Owing to its restricted expression in normal tissues and frequent upregulation in various malignancies, this peptide has become a focal point in tumor immunology research. Its unique sequence and immunogenic features make it particularly relevant for studies aiming to elucidate T-cell responses, antigen processing, and molecular interactions within the context of cancer biology.

Epitope Mapping: Cancer/testis antigen 1 (60-72) is widely utilized for mapping immunodominant epitopes recognized by cytotoxic T lymphocytes (CTLs) and helper T cells. By synthesizing and presenting this specific peptide fragment, researchers can identify and characterize the precise regions of NY-ESO-1 that elicit immune responses in cancer patients. Such studies are instrumental in understanding the landscape of antigen-specific immunity and in guiding the rational design of antigenic constructs for immunotherapy research.

Immunogenicity Assessment: The peptide is frequently employed in assays designed to evaluate the immunogenic potential of cancer/testis antigens. By incorporating this sequence into in vitro stimulation protocols, scientists can assess the activation and proliferation of T cells derived from peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating lymphocytes (TILs). These experiments provide critical insights into the cellular immune repertoire and help delineate the mechanisms underlying tumor immune surveillance.

Peptide-MHC Binding Studies: The defined sequence of this peptide enables detailed investigations into its binding affinity and stability with major histocompatibility complex (MHC) molecules. Through in vitro binding assays and structural analyses, researchers can determine the molecular determinants governing peptide presentation by MHC class I or II molecules. Such information is vital for predicting immunogenicity, optimizing peptide-based reagents, and advancing the field of antigen presentation biology.

T-Cell Receptor (TCR) Specificity Analysis: Cancer/testis antigen 1 (60-72) serves as a model antigen for probing T-cell receptor specificity and cross-reactivity. By utilizing this peptide in cellular assays or tetramer staining protocols, investigators can monitor antigen-specific T-cell populations, quantify their functional avidity, and explore the diversity of TCR repertoires in different experimental settings. These applications support the development of adoptive T-cell therapies and facilitate the monitoring of immune responses in preclinical models.

Synthetic Peptide Controls: The peptide is also employed as a positive control or reference standard in various immunological assays, including ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of antigen-specific T cells. Its defined sequence and proven immunogenicity make it an ideal benchmark for validating experimental systems, calibrating assay sensitivity, and ensuring reproducibility across different laboratories. This role is essential for the standardization and comparison of immunological data in basic and translational cancer research.

1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

2. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

3. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

4. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy